Lv38
288 积分 2026-08-06 加入
Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
1个月前
已完结
Preclinical evaluation of novel 177Lu-labeled fibroblast activation protein inhibitor with albumin binder for radioligand therapy
1个月前
已完结
Preclinical and First-in-Human Study of a Compact Radionuclide Labeled Self-Assembly Nanomedicine for Chemo-Radio-Theranostics of Cancer
1个月前
已完结
皖公网安备34019202002308
